How to buy Heron Therapeutics stock - 11 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Heron Therapeutics stock

Own Heron Therapeutics stock in just a few minutes.

Heron Therapeutics, Inc is a biotechnology business based in the US. Heron Therapeutics shares (HRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Heron Therapeutics employs 223 staff and has a trailing 12-month revenue of around USD$88.6 million.

How to buy shares in Heron Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Heron Therapeutics. Find the stock by name or ticker symbol: HRTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Heron Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Heron Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Heron Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Heron Therapeutics share price

Use our graph to track the performance of HRTX stocks over time.

Heron Therapeutics shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$13.13 - USD$22.4
50-day moving average USD$16.9029
200-day moving average USD$17.4207
Wall St. target priceUSD$34
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.562

Buy Heron Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Heron Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Heron Therapeutics financials

Revenue TTM USD$88.6 million
Gross profit TTM USD$-120,884,000
Return on assets TTM -32.11%
Return on equity TTM -70.99%
Profit margin -256.41%
Book value $2.59
Market capitalisation USD$1.6 billion

TTM: trailing 12 months

Shorting Heron Therapeutics shares

There are currently 20.5 million Heron Therapeutics shares held short by investors – that's known as Heron Therapeutics's "short interest". This figure is 2% up from 20.2 million last month.

There are a few different ways that this level of interest in shorting Heron Therapeutics shares can be evaluated.

Heron Therapeutics's "short interest ratio" (SIR)

Heron Therapeutics's "short interest ratio" (SIR) is the quantity of Heron Therapeutics shares currently shorted divided by the average quantity of Heron Therapeutics shares traded daily (recently around 864389.77702987). Heron Therapeutics's SIR currently stands at 23.77. In other words for every 100,000 Heron Therapeutics shares traded daily on the market, roughly 23770 shares are currently held short.

However Heron Therapeutics's short interest can also be evaluated against the total number of Heron Therapeutics shares, or, against the total number of tradable Heron Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Heron Therapeutics's short interest could be expressed as 0.22% of the outstanding shares (for every 100,000 Heron Therapeutics shares in existence, roughly 220 shares are currently held short) or 0.2733% of the tradable shares (for every 100,000 tradable Heron Therapeutics shares, roughly 273 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Heron Therapeutics.

Find out more about how you can short Heron Therapeutics stock.

Heron Therapeutics share dividends

We're not expecting Heron Therapeutics to pay a dividend over the next 12 months.

Have Heron Therapeutics's shares ever split?

Heron Therapeutics's shares were split on a 1:20 basis on 12 January 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heron Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Heron Therapeutics shares which in turn could have impacted Heron Therapeutics's share price.

Heron Therapeutics share price volatility

Over the last 12 months, Heron Therapeutics's shares have ranged in value from as little as $13.13 up to $22.4. A popular way to gauge a stock's volatility is its "beta".

HRTX.US volatility(beta: 1.35)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heron Therapeutics's is 1.3486. This would suggest that Heron Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Heron Therapeutics overview

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site